NCT03860272 2026-03-30Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT04028063 2026-01-27Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasUniversity of Colorado, DenverPhase 2 Recruiting65 enrolled
NCT05864534 2025-10-03Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern UniversityPhase 2 Recruiting25 enrolled
NCT04607200 2022-01-11AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaAgenus Inc.Phase 2 Withdrawn